11:02 AM EST, 12/11/2024 (MT Newswires) -- Enlivex Therapeutics ( ENLV ) said Wednesday it received authorization from the Israeli Ministry of Health to start a phase 1 clinical trial of Allocetra after injection into the temporomandibular joint in osteoarthritis patients.

The company intends to evaluate the frequency and severity of adverse events, including serious adverse events, as the primary safety endpoint of the trial, which will enroll six participants, it added.

Enlivex said that efficacy endpoints will focus on changes from baseline in temporomandibular joint pain, joint functionality, and other disease parameters for up to 12 months following the injection of Allocetra.

Shares of Enlivex Therapeutics ( ENLV ) were down 1.6% in recent trading.

Price: 1.23, Change: -0.02, Percent Change: -1.60